Hyperparathyroidism News and Research

RSS
Hyperparathyroidism is a condition in which the parathyroid gland (one of four pea-sized organs found on the thyroid) makes too much parathyroid hormone. This causes a loss of calcium from the bones and an increased level of calcium in the blood. Symptoms include bone pain and kidney problems.

In most cases doctors don't know the cause. The vast majority of cases occur in people with no family history of the disorder. Only about 5 percent of cases can be linked to an inherited problem. Familial multiple endocrine neoplasia type 1 is a rare, inherited syndrome that affects the parathyroids as well as the pancreas and the pituitary gland. Another rare genetic disorder, familial hypocalciuric hypercalcemia, is sometimes confused with typical hyperparathyroidism. Each accounts for about 2 percent of primary hyperparathyroidism cases.

In the United States, about 100,000 people develop the disorder each year. Women outnumber men two to one, and risk increases with age. In women 60 years and older, two out of 1,000 will develop hyperparathyroidism each year.
New mathematical model of bone renewal predicts the effects of osteoporosis medications

New mathematical model of bone renewal predicts the effects of osteoporosis medications

Primary hyperparathyroidism increases patients' risk of hip fracture, heart attack and stroke

Primary hyperparathyroidism increases patients' risk of hip fracture, heart attack and stroke

Effectiveness of a 'test-and-treat' approach for identification and treatment of vitamin D insufficiency for prevention of COVID-19

Effectiveness of a 'test-and-treat' approach for identification and treatment of vitamin D insufficiency for prevention of COVID-19

Drugs can help prevent progression of cardiac hypertrophy in hemodialysis patients

Drugs can help prevent progression of cardiac hypertrophy in hemodialysis patients

Researchers discover signaling protein that may protect parathyroid glands from hyperactivity

Researchers discover signaling protein that may protect parathyroid glands from hyperactivity

Mild cognitive impairment may be present in early stages of kidney disease

Mild cognitive impairment may be present in early stages of kidney disease

FDA authorizes two devices that provide real-time location of parathyroid tissue during surgery

FDA authorizes two devices that provide real-time location of parathyroid tissue during surgery

Endocrine Society announces winners of prestigious 2019 Laureate Awards

Endocrine Society announces winners of prestigious 2019 Laureate Awards

New minimally invasive approach to diagnose hyperparathyroidism

New minimally invasive approach to diagnose hyperparathyroidism

Study provides new insights into molecular basis of CaSR-related human diseases

Study provides new insights into molecular basis of CaSR-related human diseases

Surgery better than widely used drugs for treating hyperparathyroidism

Surgery better than widely used drugs for treating hyperparathyroidism

Parathyroid hormone may mediate antihypertensive fracture risk

Parathyroid hormone may mediate antihypertensive fracture risk

Surgery more effective than drug therapy in patients with tertiary hyperparathyroidism

Surgery more effective than drug therapy in patients with tertiary hyperparathyroidism

International research project examines effectiveness of tried and tested medicines for different diseases

International research project examines effectiveness of tried and tested medicines for different diseases

Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide

Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide

Scientists discover the oldest case of leukemia in prehistoric female skeleton

Scientists discover the oldest case of leukemia in prehistoric female skeleton

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio purchases entire equity interest in Zhejiang Wansheng

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Paediatric primary hyperparathyroidism in rarely a familial disorder

Paediatric primary hyperparathyroidism in rarely a familial disorder

Chronic heart failure patients with decreased calcitriol may benefit from aggressive supplementation

Chronic heart failure patients with decreased calcitriol may benefit from aggressive supplementation